People

Erica Stutz is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Yale University. This is an advisory or cohort network affiliation, rather than a firm employee position.

Henry La Soya is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Novo Holdings. This is an advisory or cohort network affiliation, rather than a firm employee position. Henry joined Novo Holdings Equity US in October 2021 as an Associate in Principal investments. He participates in deal sourcing and execution and manages investments across the healthcare sector as a part of our Boston office. Prior to Novo Holdings, Henry served as a consultant at Roland Berger for two years, primarily focusing on the industrials space. He also began his career with consulting internships in the healthcare space at Clarion and Thrive Consulting. Henry holds a BS in Bioengineering with a Finance minor from Massachusetts Institute of Technology (MIT).

Kate Schnitzer is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as The Wharton School at the University of Pennsylvania. This is an advisory or cohort network affiliation, rather than a firm employee position.

Aaron Sacks is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as UnitedHealth Group. This is an advisory or cohort network affiliation, rather than a firm employee position.

Amalia Roth is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Kellogg School of Management at Northwestern University. This is an advisory or cohort network affiliation, rather than a firm employee position.

Jeff Rosenzweig is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Inova Health Systems. This is an advisory or cohort network affiliation, rather than a firm employee position.

Jack Rogoff is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Fresenius. This is an advisory or cohort network affiliation, rather than a firm employee position.

Glenna Roberts is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Harvard Business School, Harvard Kennedy School. This is an advisory or cohort network affiliation, rather than a firm employee position.

Mckenzie Rhone is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Chicago Booth. This is an advisory or cohort network affiliation, rather than a firm employee position.

Nathaniel Perez is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Duke University, Fuqua School of Business. This is an advisory or cohort network affiliation, rather than a firm employee position.

Sara Parsons is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Point32Health. This is an advisory or cohort network affiliation, rather than a firm employee position.

Shreeya Panigrahi is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Stanford University. This is an advisory or cohort network affiliation, rather than a firm employee position.

Murtaza Mubin is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Stanford University. This is an advisory or cohort network affiliation, rather than a firm employee position.

Marcy Medlak is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Elevance Health. This is an advisory or cohort network affiliation, rather than a firm employee position.

Michelle Matvey is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as MIT Sloan. This is an advisory or cohort network affiliation, rather than a firm employee position.

John Machalek is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Elevance Health. This is an advisory or cohort network affiliation, rather than a firm employee position.

Brett Libowitz is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as University of Pennsylvania, The Wharton School. This is an advisory or cohort network affiliation, rather than a firm employee position.

Zoey Li is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as MIT Sloan. This is an advisory or cohort network affiliation, rather than a firm employee position.

Pranav Kuber is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Piction Health. This is an advisory or cohort network affiliation, rather than a firm employee position.

Christine Kohn is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Harvard T.H. Chan School of Public Health. This is an advisory or cohort network affiliation, rather than a firm employee position.

Priya Khatri is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Memorial Hermann. This is an advisory or cohort network affiliation, rather than a firm employee position.

Jesse Kesner is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Harvard University. This is an advisory or cohort network affiliation, rather than a firm employee position.

Lea Jabbour is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as University of Chicago Booth School of Business. This is an advisory or cohort network affiliation, rather than a firm employee position.

Ellie Hwang is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as MedStar. This is an advisory or cohort network affiliation, rather than a firm employee position.

John Hwang is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as University of Pennsylvania, The Wharton School. This is an advisory or cohort network affiliation, rather than a firm employee position.

Jessie Huang is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Tuck School of Business. This is an advisory or cohort network affiliation, rather than a firm employee position.

Lawrence Huang is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Warren Alpert Medical School of Brown University. This is an advisory or cohort network affiliation, rather than a firm employee position.

Sarah Holmes is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Cleveland Clinic. This is an advisory or cohort network affiliation, rather than a firm employee position.

Charlotte Grimm is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Kellogg School of Management at Northwestern University. This is an advisory or cohort network affiliation, rather than a firm employee position.

Dominik Gorecki is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as University of California, Berkeley. This is an advisory or cohort network affiliation, rather than a firm employee position.

Jim Fitzgerald is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Knownwell. This is an advisory or cohort network affiliation, rather than a firm employee position.

Ethan Emde is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as AdventHealth. This is an advisory or cohort network affiliation, rather than a firm employee position.

Bradley Dollens is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Parkview Health. This is an advisory or cohort network affiliation, rather than a firm employee position.

Mary Dinnean is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Boston University. This is an advisory or cohort network affiliation, rather than a firm employee position.

Kendall Dexter is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Blue Cross NC. This is an advisory or cohort network affiliation, rather than a firm employee position.

Micah Dean is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Cincinnati Children's. This is an advisory or cohort network affiliation, rather than a firm employee position.

Rahina Damji is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Columbia Business School. This is an advisory or cohort network affiliation, rather than a firm employee position.

Andrew Croll is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as CVS Health. This is an advisory or cohort network affiliation, rather than a firm employee position.

Prasidh Chhabria is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Percepta. This is an advisory or cohort network affiliation, rather than a firm employee position.

Henry Chen (Apple) is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Apple. This is an advisory or cohort network affiliation, rather than a firm employee position. This Apple/Google Health clinical-operations professional is distinct from the Delos Capital investor of the same name.

Madeline Chaillet is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as University of Virginia Darden School of Business. This is an advisory or cohort network affiliation, rather than a firm employee position.

Candace Carlson is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Hartford Healthcare. This is an advisory or cohort network affiliation, rather than a firm employee position.

Jack Cai is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Boston Children's Hospital. This is an advisory or cohort network affiliation, rather than a firm employee position.

Brandy Bittenbender is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as LabCorp. This is an advisory or cohort network affiliation, rather than a firm employee position.

Jesse Bissen is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Allina Health. This is an advisory or cohort network affiliation, rather than a firm employee position.

Justin Bier is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Cox. This is an advisory or cohort network affiliation, rather than a firm employee position.

Julien Bendelac is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Stanford University. This is an advisory or cohort network affiliation, rather than a firm employee position.

Vanessa Baillie is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Medtronic. This is an advisory or cohort network affiliation, rather than a firm employee position.

Rushil Arora is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Pomelo Care + Stanford University. This is an advisory or cohort network affiliation, rather than a firm employee position.

Maya Ambady is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as University of Michigan. This is an advisory or cohort network affiliation, rather than a firm employee position.

Brett Adkins is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Boston Children's Hospital. This is an advisory or cohort network affiliation, rather than a firm employee position.

Matt Stein is listed in Flare Capital Partners’ current public directory as AI Advisory Council member. The directory describes the external professional affiliation as Chief Information Officer. This is an advisory or cohort network affiliation, rather than a firm employee position.

William Sheahan is listed in Flare Capital Partners’ current public directory as AI Advisory Council member. The directory describes the external professional affiliation as Senior Vice President and Chief Innovation Officer. This is an advisory or cohort network affiliation, rather than a firm employee position.

Brandon Seibold is listed in Flare Capital Partners’ current public directory as AI Advisory Council member. The directory describes the external professional affiliation as Chief Growth Officer and Treasurer. This is an advisory or cohort network affiliation, rather than a firm employee position.

Jared Saul is listed in Flare Capital Partners’ current public directory as AI Advisory Council member. The directory describes the external professional affiliation as Former Chief Medical Officer, Commercial Health & Life Sciences (External Advisor). This is an advisory or cohort network affiliation, rather than a firm employee position.

Todd Ponsky is listed in Flare Capital Partners’ current public directory as AI Advisory Council member. The directory describes the external professional affiliation as Chief Innovation Officer. This is an advisory or cohort network affiliation, rather than a firm employee position.

Ganesh Persad is listed in Flare Capital Partners’ current public directory as Flare Scholar, 2026 cohort. The directory describes the external professional affiliation as Vice President & Chief Information Officer. This is an advisory or cohort network affiliation, rather than a firm employee position.

Tilak Mandadi is listed in Flare Capital Partners’ current public directory as AI Advisory Council member. The directory describes the external professional affiliation as Executive Vice President, Ventures and Chief Experience and Technology. This is an advisory or cohort network affiliation, rather than a firm employee position.

Katie Catlender is listed in Flare Capital Partners’ current public directory as AI Advisory Council member. The directory describes the external professional affiliation as Executive Vice President and Chief Operating Officer. This is an advisory or cohort network affiliation, rather than a firm employee position.

Sean Bruich is listed in Flare Capital Partners’ current public directory as AI Advisory Council member. The directory describes the external professional affiliation as Chief Technology Officer. This is an advisory or cohort network affiliation, rather than a firm employee position.

Svetlana Bender is listed in Flare Capital Partners’ current public directory as AI Advisory Council member. The directory describes the external professional affiliation as Vice President, Artificial Intelligence & Behavioral Science. This is an advisory or cohort network affiliation, rather than a firm employee position.

Jeff Weiss is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as Executive Vice President, Enterprise Strategy & Strategic Partnerships. This is an advisory or cohort network affiliation, rather than a firm employee position.

Marcus Wallace is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as Chief Medical Officer and Vice President, Clinical Operations and Innovation. This is an advisory or cohort network affiliation, rather than a firm employee position.

Zoey Ma is an AI Engineer at Knit Health Technologies. The company identifies her in a named public team testimonial, alongside an authentic portrait. She describes joining Knit to work on cutting-edge AI research that improves people’s lives; the company develops Large Clinical Behavior Models for healthcare systems.

Midori Uehara is Chief Growth Officer of Knit Health Technologies. The current company roster identifies her leadership role, and her own public launch announcement confirms joining the company’s clinical intelligence team. Knit develops healthcare AI trained on real clinical decisions and patient pathways.

Anna Zink is Head of Data Science at Knit Health Technologies. She is named on the company’s current leadership roster and is a co-author of the foundational Deep Causal Behavioral Policy Learning: Applications to Healthcare research with Jonas Knecht, Jonathan Kolstad and Maya Petersen. Her work contributes to the causal and behavioral modeling underlying Knit’s healthcare AI.

Ted Robertson is co-founder and Chief Operating Officer of Knit Health Technologies and executive director of UC Berkeley’s Center for Healthcare Marketplace Innovation. His background in behavioral economics, product design and organization building supports translating Knit’s clinical intelligence research into products health systems can deploy.

Anshul Amar is Co-Chief Technology Officer of Knit Health Technologies, serving alongside co-founder Jonas Knecht. He is named on the company’s current public leadership roster. His public professional profile identifies healthcare technology experience and patents concerning automated image classification, provider negotiated rates, and practice management and billing automation.

Jonas Knecht is co-founder and Co-Chief Technology Officer of Knit Health Technologies. A UC Berkeley doctoral researcher in econometrics and computational precision health, he developed the computational architecture behind Knit’s Large Clinical Behavior Model. His work combines behavioral data and computational methods to model clinical decisions.

Sophie Pinkard is Chief Product Officer of Knit Health Technologies. The company’s public roster and named testimonial identify her product leadership role in applying clinical intelligence to healthcare workflows and improving care delivery. Her public professional biography describes experience leading healthcare product teams.

Maya Petersen is co-founder and Chief Scientist of Knit Health Technologies. A physician and UC Berkeley professor of epidemiology, biostatistics and computational precision health, she is co-director of the joint UCSF–UC Berkeley Computational Precision Health programme. Her causal inference expertise informs Knit’s efforts to distinguish observed clinician behavior from optimal patient-specific decisions.

Jonathan Kolstad is co-founder and CEO of Knit Health Technologies, the UC Berkeley spinout developing Large Clinical Behavior Models for healthcare. He is a UC Berkeley Haas professor and Henry J. Kaiser Chair in Economic Analysis and Policy. His research on healthcare economics and clinical decision-making helped establish Knit’s behavioral approach to healthcare AI.

Rick Talento is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as Chief Financial Officer. This is an advisory or cohort network affiliation, rather than a firm employee position.

Chase Tacker is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as Senior Vice President, Corporate Development. This is an advisory or cohort network affiliation, rather than a firm employee position.

Barry Stein is listed in Flare Capital Partners’ current public directory as AI Advisory Council member. The directory describes the external professional affiliation as Vice President, Chief Clinical Innovation Officer and Chief Medical Informatics Officer. This is an advisory or cohort network affiliation, rather than a firm employee position.

Sue Siegel is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as Former Chief Innovation Officer and Former Chief Executive Officer. This is an advisory or cohort network affiliation, rather than a firm employee position.

Susan K. Nelson is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as Executive Vice President and Chief Financial Officer. This is an advisory or cohort network affiliation, rather than a firm employee position.

Matthew Morgan is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as Senior Vice President and Chief Financial Officer. This is an advisory or cohort network affiliation, rather than a firm employee position.

Juan Lopez is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as Executive Vice President, Chief Financial Officer, and Treasurer. This is an advisory or cohort network affiliation, rather than a firm employee position.

Jessica Lee-Hansen was named chief financial officer for Parkview Health in July 2025. She is responsible for management oversight and direction over financial strategy and planning, accounting and reporting, capital planning, revenue cycle services, and treasury. As a member of Parkview’s executive leadership team, she serves as a strategic financial advisor to executives and the board of directors. Prior to joining Parkview, Lee-Hansen worked as an investment banker for two global financial services organizations, starting as a summer analyst and working her way up to a managing director position. She served as a strategic financial advisor to an impressive and diverse portfolio of clients, including health systems, physician groups, value-based organizations, and payors. Lee-Hansen has also been recognized as an emerging leader, participating in a variety of leadership programs and councils. Her experience, which is vital to supporting continued growth, helps drive Parkview’s mission to improve health and inspire well-being. Lee-Hansen holds a bachelor of arts in economics and political science from Columbia University. Her existing FlareCapitalPartners externalIndustryAdvisoryBoard affiliation is separately preserved.

Isaac Kohane is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as Professor and Chair, Department of Biomedical Informatics. This is an advisory or cohort network affiliation, rather than a firm employee position. A physician and biomedical informatics researcher, known as Zak, whose work includes medical artificial intelligence and neurodevelopmental genomics.

Kelly Ko is listed in Flare Capital Partners’ current public directory as AI Advisory Council member. The directory describes the external professional affiliation as Vice President of Technology Ventures and Innovation. This is an advisory or cohort network affiliation, rather than a firm employee position.

Timothy Howe is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as Assistant Vice President, Health Care Strategy and Investments. This is an advisory or cohort network affiliation, rather than a firm employee position.

Gregory Grunberg is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as Head of Life Sciences & Healthcare, North America. This is an advisory or cohort network affiliation, rather than a firm employee position.

Jonathan Gruber is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as Ford Professor, Economics and Chairman, Economics Department. This is an advisory or cohort network affiliation, rather than a firm employee position.

Jeffrey E. Graff is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as Senior Vice President/Treasury and Chief Corporate Development Officer. This is an advisory or cohort network affiliation, rather than a firm employee position.

Steven C. Glass is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as Former President and Chief Executive Officer. This is an advisory or cohort network affiliation, rather than a firm employee position.

Beau Garverick is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as Senior Vice President, Corporate Development and Strategy. This is an advisory or cohort network affiliation, rather than a firm employee position.

Aaron Foster is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as Vice President, Business Analytics and Insights. This is an advisory or cohort network affiliation, rather than a firm employee position.

Sandra L. Fenwick is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as Chief Executive Officer, Emeritus. This is an advisory or cohort network affiliation, rather than a firm employee position.

Jeffrey Fedder is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as Head of Corporate Development and Strategic Investments. This is an advisory or cohort network affiliation, rather than a firm employee position.

Yao Fang is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as Executive President. This is an advisory or cohort network affiliation, rather than a firm employee position.

Justin Strausbaugh is named as a manager of TensilityIII LLC in its July2026 regulatory filing, alongside Tensility co-founders Wayne Boulais and Armando Pauker. His former employer Alumni Ventures identifies him as the former managing partner of Lakeshore Ventures and a University of Chicago Booth graduate. The current Tensility website directory omits Justin; the legal vehicle role is dated to the2026 filing rather than inferred from an undated third-party partner title.

Investor and company director across ICT, technology, medical technology and circular economy; CEO of Foregreen Investments and chairman of Profium.

Medical-device entrepreneur, investor and adviser to growth companies, with experience developing medical software businesses.

Business leader with experience in international sales and marketing at Instrumentarium, SpaceLabs Healthcare and GE Healthcare, including operating-room and intensive-care monitoring businesses.

Investor and company director with a background as a partner at Roschier and experience in mergers and acquisitions, healthcare, retail and ICT.

Sreekanth Chaguturu is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as Executive Vice President and​ Chief Medical Officer​. This is an advisory or cohort network affiliation, rather than a firm employee position.

Brian Caveney is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as Chief Medical and Scientific Officer. This is an advisory or cohort network affiliation, rather than a firm employee position. Labcorp public biography: Brian Caveney, M.D., J.D., M.P.H. Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer Brian Caveney, M.D. has served as Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer at Labcorp since September 2026 and previously served as Labcorp’s Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer at Labcorp from 2023 to 2026. From 2019 to 2023, he served as EVP and President, Diagnostics and Chief Medical Officer. From 2017 to 2019, he served as Senior Vice President and Chief Medical Officer. In his current role, Brian leads our global biopharma laboratory services business, in addition to medical and scientific affairs, research and development, and quality for Labcorp. Since joining Labcorp in 2017, Brian has been instrumental in accelerating growth in the company’s business units and advancing its medical and scientific strategy. Under his leadership, the company has expanded diagnostic testing services, introduced new assays across key therapeutic areas, and expanded its hospital strategy. During the COVID-19 pandemic, Brian led efforts to expand the accessibility of PCR testing, used his expertise to help bring understanding about testing and treatment options to the public, and drove advancements to the way the company works with the broader healthcare industry. Before joining Labcorp in 2017, Brian was the Chief Medical Officer at Blue Cross and Blue Shield of North Carolina. In addition to various roles in the healthcare division of the core health plan, Brian also served as Chief Clinical Officer of Mosaic Health Solutions, a wholly-owned subsidiary of Blue Cross NC, for strategic investments in diversified health solutions businesses. Previously, he was a practicing physician and assistant professor at Duke University Medical Center. Brian serves on the Board of Directors of the Personalized Medicine Coalition, the Healthcare Leadership Council, and North Carolina Healthcare Quality Alliance. He is a Board Observer for CND Life Sciences, Inc. He holds a Doctor of Medicine from the West Virginia University School of Medicine, a Juris Doctorate from the West Virginia University College of Law, and a Master of Public Health from the University of North Carolina at Chapel Hill. He completed his residency at Duke University Medical Center and is board certified in preventive medicine, with a specialty in occupational and environmental medicine.

Thomas Brouillard is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as CFO Global Care Delivery. This is an advisory or cohort network affiliation, rather than a firm employee position.

Jen Barrera is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as Senior Vice President, Strategic Implementation. This is an advisory or cohort network affiliation, rather than a firm employee position.

Chris Hocevar is listed in Flare Capital Partners’ current public directory as Executive Partner. The manager’s own biography documents this healthcare investment, operating or platform position.

Phyllis Gotlib is listed in Flare Capital Partners’ current public directory as Executive Partner. The manager’s own biography documents this healthcare investment, operating or platform position.

Graham Gardner is listed in Flare Capital Partners’ current public directory as Executive Partner. The manager’s own biography documents this healthcare investment, operating or platform position.

Flare controller supporting finance and operations since2025. Previously managed private-equity and venture fund reporting at Summit Partners and spent eight years in KPMG audit, reaching senior manager. A Massachusetts CPA and UMass Amherst accounting graduate.

Flare senior associate supporting healthcare technology investments. Previously advised pharmaceutical and healthcare companies at ZS Associates on innovation, digital strategy, analytics organization and commercial diligence; her own biography also describes venture experience at53Stations.

Flare executive assistant who joined inJuly2024 and supports investment and platform leadership. Previously worked in office and operations administration at B-FLEXION. Earned a sociology degree at Bridgewater State University.

Flare principal with experience incubating healthcare startups at Redesign Health and leading operations and strategy work at Flatiron Health. Earlier advised pharmaceutical commercialization and market access at Putnam Associates. Holds a McGill economics degree and Wharton MBA.

Executive assistant at Flare, joining inDecember2024 to support partners Michael Greeley, Adam Bruce, Ian Chiang and Margaret Malone. Previously supported Cohere Health’s executive leadership as operations coordinator. A University of Maryland public-health graduate.

Flare partner focused on technology-supported care, payer/provider infrastructure, healthcare workforce and life-sciences platforms. Earlier helped healthcare founders build executive teams at Oxeon, invested at7wire and B Capital, and advised clinical operations at Huron.

Healthcare venture partner at Flare, also known as Vic. His own biography identifies leadership of investments in Elektra Health, Greater Good Health, Lynx and Ounce of Care. Previously worked in Curaspan corporate development and naviHealth product strategy, with earlier healthcare consulting at PwC and McKinsey.

Flare senior associate investing in healthcare software, data and artificial intelligence. Previously led AI strategy work at Harvard Medical School and held data engineering and business-strategy roles at PathAI. Earned an MIT Sloan MBA and also appears in the firm’s2026 Scholar cohort; the later senior-associate biography controls her staff position.

Flare vice president leading investor relations and fundraising communications. Previously worked in investor relations at RA Capital and Bain Capital, corporate development at Relay Therapeutics, and investment consulting at Cambridge Associates.

Brian Ames formerly served as managing director and head of growth at Anthos Capital. Savers Value Village’s April 2026 proxy explicitly describes the Anthos role as former, overriding stale investor directories. His previous operating experience included president and general manager of Activision Blizzard Media. He joined Anthos in 2021 according to issuer biographies, but an exact departure day is unpublished and not inferred from his August 2025 Savers board appointment. Distinct from the actor and unrelated people with this name.

Frances Au-yang’s own public professional profile identifies a Santa Monica-based Anthos Capital affiliation and study at the University of California, Los Angeles from 2005 to 2009. A precise current functional title and independently sourced full biography are not published in the accessible primary profile; a third-party vice-president title is not assumed.

Sue Choe is publicly affiliated with Anthos Capital in her current professional profile and own recruiting posts. Her 2024 conference biography identifies her as head of people and portfolio talent, supporting both the firm and portfolio companies, following people-leadership roles at Petal and Venmo. She studied at Harvard Business School. The published 2024 title is qualified; no later COO promotion is asserted without primary confirmation. Her named original conference portrait is not retrievable; no replacement portrait is invented.

Andrew Cafourek’s own professional website identifies him as VP and head of technology at Anthos Capital, managing technical infrastructure and evaluating emerging technology for internal workflows. His biography describes prior product and digital-technology work at Lat Long and Alumni Spaces. He received a 2022 master’s in global management with a space-leadership, business and policy specialization at Thunderbird/Arizona State and studied political science at Missouri. The VP title is reproduced from the primary biography; a later promotion is not independently asserted.

Bryan Hale is an investor at Anthos Capital and is publicly named as an organizing-team member of the April 2026 Seattle AI Startup Summit. His own professional announcement describes joining Anthos following four years at the Allen Institute for AI Incubator and continuing a separate incubator-fund investor affiliation. Harvard education is published on his own profile. He is distinct from Haley Bryant and other similar-name people.

Emily White is president of Anthos Capital, serving since 2018 according to current issuer biographies. Her previous technology leadership included COO of Snap and roles at Instagram, Facebook and Google. Lululemon’s current director biography describes her oversight of investments including Gretel.ai and Laurel.ai and her work in digital advertising and emerging technologies. She holds a Vanderbilt art-history degree. This executive is distinct from the existing Greenbrook clinical-operations professional also named Emily White.

Gavyn Davies is a limited partner and control person of Anthos Management in its March 2026 regulatory filing, recorded since July 2007. This identifies ownership of the management partnership, not a proven day-to-day executive job or a particular portfolio-company check. His current Fulcrum Asset Management biography identifies him as founder and executive chairman, formerly BBC chairman and Goldman Sachs chief economist, with Cambridge economics study and Oxford research.

Yvonne I. Pytlik is named as Anthos Capital’s chief compliance officer in its March 2026 ADV, with the role recorded since July 2022. Columbia University’s current faculty biography identifies her as an outsourced chief compliance officer at ACA Group and an enterprise risk management lecturer. Her earlier compliance leadership includes HSBC and Deutsche Bank. This is a source-qualified outsourced compliance affiliation, not an assumed internal employment arrangement.

Randall Robert Chandler, publicly known as Randy Chandler, is chief financial officer of Anthos Management, the legal adviser operating as Anthos Capital. The March 30, 2026 ADV names him as CFO and records the role since February 2020; he signed that filing as CFO. His own professional profile lists USC Marshall education, CFA qualification and inactive CPA status. Exact appointment day is not inferred from a month/year.

Bryan Francis Kelly is a co-founder and principal owner of Anthos Capital. The firm’s March 2026 ADV names him as a limited partner and control person since July 2007, and July 2026 issuer SEC filings identify him and Paul Farr as managers of Anthos Management and related fund general partners. His own professional profile identifies Stanford Law School study. Distinct from the composer and unrelated investors sharing this name.

Jeffrey Paul Farr, publicly known as Paul Farr, co-founded and co-leads Anthos Capital. Its March 2026 ADV identifies him as a principal owner and limited partner since July 2007. Cambrian Bio’s current director biography describes his previous investment work at Summit Partners and Goldman Sachs and degrees from McGill and Stanford. He also serves on Cambrian’s board; no personal financing participation is inferred.

Healthcare venture investor known as Jon or JG, serving as Flare vice president. Focuses on care delivery, AI and machine learning, with earlier experience at OCA Ventures, Wittington Ventures, Mayo Clinic and healthcare consultancy Chartis. Was a Flare Scholar in2022.

Physician and healthcare investor serving as Flare partner. Practiced internal medicine at Massachusetts General Hospital and taught at Harvard Medical School from2010–2019. Earlier Harvard Pilgrim medical-director work covered population-health analytics and value-based purchasing, alongside health-technology entrepreneurship and policy advising.

Flare vice president responsible for marketing and platform support, including communications, content, events and healthcare ecosystem partnerships. Previously researched digital health at CB Insights and was an early Health Tech Nerds team member.

Flare healthcare investment partner with experience in policy, operations and venture investing. His current primary biography describes involvement with clinical AI at SmarterDx, Daffodil, Layer and Photon, and earlier healthcare AI investing at NewYork-Presbyterian Ventures. Company board appointments and personal cash attribution are not inferred from this summary.

Healthcare venture finance and operations executive, serving as Flare partner, CFO and COO. Previously spent more than14years at Advanced Technology Ventures, including CFO, and also served as Lightstone Ventures CFO. Earlier worked in investment banking at DLJ and Credit Suisse First Boston.

Roel Kellenaers served as MRIguidance CEO from January 2025 until February 2026, when Guido Zijl succeeded him. The issuer announced his CEO appointment on 23 January 2025 after 14 months as Chief Commercial Officer. It describes marketing, sales, strategy and business-development experience in life sciences. An exact CCO start day is not inferred from the month-level duration.

Roel Raatgever co-founded MRIguidance with Peter Seevinck and Marijn van Stralen in 2016 and served as CEO. The issuer announced his death on 1 December 2021 after a traffic accident during a US business trip. It named the two other founders as temporarily covering his leadership duties. The exact day of death is not disclosed, so the announcement date is not entered as an invented tenure end.

René Castelein is a member of MRIguidance’s current medical advisory board, as named by the company. His research co-authorship and genuine issuer portrait support the scientific affiliation but do not establish an executive position or personal investment.

Kornelis Poelstra is a member of MRIguidance’s current medical advisory board. The issuer also describes his BoneMRI spine-surgery work at the Robotic Spine Institute of Las Vegas. The advisory role and clinical use do not establish a personal financing check.

Addie Harris is a member of MRIguidance’s current advisory board, as named by the company. Her genuine portrait is published beside the named affiliation. The appointment date and any personal equity investment are undisclosed.

Tijl van der Velden is MRIguidance’s Clinical MRI Specialist. His current company biography describes implementing MRI sequences, managing artifacts and improving patient comfort while obtaining data for the deep-learning team.

Stijn van Wijngaarden is MRIguidance’s Deep Learning Engineer. The current company directory describes combining MR physics and deep learning to develop medical-imaging technology for healthcare.

Rick Bergmans is MRIguidance’s Deep Learning Lead. His current issuer biography describes developing clinically relevant deep-learning solutions and structured, high-quality medical-imaging data pipelines.

Manuela Escobar is MRIguidance’s Marketing & Communications Manager. The current company directory identifies her work communicating BoneMRI to clinicians and healthcare partners. Its linked personal profile uses the fuller name Manuela Escobar Sanz de Santa Maria.

Kees van Wijk is MRIguidance’s Senior Software Architect. According to the current company directory, he has more than 15 years of experience in the medical domain and focuses on practical software solutions. His exact appointment date is not published.

Hilde Geraedts is MRIguidance’s Senior Clinical Affairs Manager. The current company directory describes experience in clinical and scientific research across medical fields, used to develop the clinical evidence supporting BoneMRI.

Jasper van der Graaf is MRIguidance’s Clinical Affairs Manager. The current company directory describes using experience in MRI and orthopedic surgery to bring imaging solutions into clinical practice. This role does not itself establish a medical degree or personal equity investment.

Iulia Lucaciu is MRIguidance’s QA Officer. Her current issuer biography describes a background in medical imaging and work developing and improving the quality management system against applicable regulations and guidelines.

Florian Calvet is MRIguidance’s DevSecOps Engineer. The current company directory describes implementing cloud technologies to make BoneMRI available to users while maintaining software security. No unpublished appointment date is inferred.

Huiqin Chen is MRIguidance’s Medical Device Software Engineer. The current issuer directory describes developing safe and reliable software applications for medical devices. The accessible directory does not link a personal profile, so unrelated professionals with the same name are not merged into this identity.

Harriet Weir is MRIguidance’s Clinical Commercial Specialist. Her current company biography describes combining biomedical engineering and commercial experience to connect clinicians with BoneMRI. No clinical licence or undisclosed executive title is inferred.

Elco Oost is MRIguidance’s Product Integration Specialist. His current company biography covers application development and certification, product deployment and customer service, supporting the introduction of BoneMRI into clinical workflows.

Dionysios Ziogas is MRIguidance’s Commercial Development Manager. The company describes his responsibility for global BoneMRI product strategy, combining health-economics knowledge and marketing expertise. The exact current spelling follows the named company directory and its linked professional profile.

Dacina Crainic is MRIguidance’s Head of Software Engineering. The current issuer directory describes her work with development teams building software products for healthcare professionals and patient care. Her engineering leadership is distinct from an inferred corporate officer or investor role.

Bram Kooiman is a Deep Learning Engineer at MRIguidance. The current company directory identifies his work in deep learning and artificial intelligence for medical-imaging applications. His exact appointment date and any personal investment are not disclosed.

Bas Buijtenhuis is MRIguidance’s Customer Service & Support Engineer. The current company directory describes a biomedical-engineering and IT background used to support customers with technical needs involving BoneMRI. No undisclosed appointment date or executive position is inferred.

Peter Seevinck is MRIguidance’s co-founder and CSO, an MR physicist and inventor of BoneMRI. He co-founded the business in 2016 and was interim CEO from early 2022 until January 2025. His current CSO work includes clinical validation, scientific and product innovation and intellectual property. UMC Utrecht independently confirms his academic research and co-founder identity. His personal scientific grants are distinct from company financing.

Marijn van Stralen is MRIguidance’s co-founder and CTO. An image scientist, he co-founded the UMC Utrecht spinout in 2016 with Peter Seevinck and Roel Raatgever. He leads medical-imaging and AI technology, the product roadmap and customer requirements. The issuer also named him among the founders temporarily covering CEO duties after Raatgever’s death in late 2021.

Guido Zijl became MRIguidance CEO in February 2026, succeeding Roel Kellenaers. The issuer describes more than 20 years of operational and commercial leadership in medical devices, most recently as a vice president at Globus Medical. The appointment month is verified; an exact effective day is not disclosed.

Eva Hukshorn is MRIguidance’s current CFO. The company announced her appointment as Chief Financial and Operations Officer on 18 October 2021, describing experience in scaling businesses and financial and operational management. The current directory uses the shorter CFO title.

Listed in Tensility Venture Partners’ current public team of advisors. The firm invests in early-stage AI-first software and services.

Listed in Tensility Venture Partners’ current public team of advisors. The firm invests in early-stage AI-first software and services.

Listed in Tensility Venture Partners’ current public team of advisors. The firm invests in early-stage AI-first software and services.

Listed in Tensility Venture Partners’ current public team of advisors. The firm invests in early-stage AI-first software and services.

Listed in Tensility Venture Partners’ current public team of advisors. The firm invests in early-stage AI-first software and services.

Listed in Tensility Venture Partners’ current public team of advisors. The firm invests in early-stage AI-first software and services.

Listed in Tensility Venture Partners’ current public team of advisors. The firm invests in early-stage AI-first software and services.

Listed in Tensility Venture Partners’ current public team of advisors. The firm invests in early-stage AI-first software and services.

Listed in Tensility Venture Partners’ current public team of advisors. The firm invests in early-stage AI-first software and services.

Listed in Tensility Venture Partners’ current public team of advisors. The firm invests in early-stage AI-first software and services.

Listed in Tensility Venture Partners’ current public team of advisors. The firm invests in early-stage AI-first software and services.

Listed in Tensility Venture Partners’ current public team of advisors. The firm invests in early-stage AI-first software and services.

Listed in Tensility Venture Partners’ current public team of advisors. The firm invests in early-stage AI-first software and services.

Listed in Tensility Venture Partners’ current public team of advisors. The firm invests in early-stage AI-first software and services.

Co-founder and general partner of Tensility Venture Partners since 2016, focusing on infrastructure software and security. Previously an Apex Venture Partners general partner. Holds a University of Michigan MBA and a Caltech electrical-engineering degree.

Co-founder and general partner of Tensility Venture Partners since 2016, focusing on application software and services. Previously an Apex Venture Partners general partner. Holds an MIT MBA and electrical-engineering degrees from UMass Amherst.

Jason Pesterfield is an independent board director of Spiro Robotics. ElucentMedical’s current official leadership directory separately identifies him as president and CEO of its precision-guided surgical technology business. His Spiro governance affiliation and outside executive role are distinct; neither establishes that ElucentMedical or he personally invested in Spiro.

Barry Cheskin is a senior adviser to Spiro Robotics, according to its current core team directory. An issuer-submitted2023 Connectpreneur financing profile also lists him among the leadership of the handheld intubation-robot company. That historic company summary does not establish a current employee title, directorship or personal investment; his current role is recorded exactly as senior adviser.

Vladimir Nekhendzy is founder and a board director of Spiro Robotics. StanfordUniversity identifies him as a clinical professor of anesthesiology, perioperative and pain medicine and, by courtesy, otolaryngology. His clinical focus includes difficult and advanced airway management and anesthesia for head-and-neck procedures. He completed anesthesiology residency at UCSF in1996 and earned board certification in1997. His clinical expertise informs the company’s physician-guided airway technology.

Jackie Dulken is director of engineering and operations at Spiro Robotics. The officialFDA K253437 decision letter and device summary identify her as the company’s regulatory contact for Spiro-VISTA. The2024 federal STTR award also lists her as business contact. Her self-published profile records mechanical engineering-related study at CaliforniaPolytechnicStateUniversity, SanLuisObispo, including a2015–2016 VarianMedicalSystems sponsored design project.

Trae Gordon is chief commercial officer of Spiro Robotics, as named in its current core team directory. The company’s own announcement identifies him as representing its airway-management technology at the2026 MedTechStrategist Innovation Summit in Dublin. His role concerns commercial development of the handheld robotic intubation platform; unpublished prior employers or credentials are not inferred.

Dimitri Sokolov is CEO and a board director of Spiro Robotics. In his first-person2024 LSIUSA presentation he describes developing a handheld image-guided robot for difficult tracheal intubation, a completed4.5Mseed raise and plans for clinical development and an AI-assisted successor. The official2024 STTR award identifies him as principal investigator for the company’s airway-management research. The firm’s FDA-cleared2026 product and future autonomousAI roadmap are separate.

Pam Ryan appears in True Wealth Ventures’ published adviser and LP network. She founded Tingari Group and has written on venture-capital behavior, microfinance and social entrepreneurship, with prior leadership in psychology and public-policy organizations. This advisory affiliation is distinct from an employee role or undisclosed personal financial check.

Susan K. Nestegard is listed in True Wealth Ventures’ LP/adviser network. Her background includes technical, healthcare and operating leadership at Ecolab and a long career at3M. Outside-board affiliations mentioned in older biographies are historical context; current appointments are not inferred.

Laurie Felker Jones is a visiting partner at True Wealth Ventures, working on fund and portfolio operations and impact. Her published background includes fractional operating-partner work and study at UT Austin, London School of Economics and Oxford. Other personal or alternative-fund projects do not automatically become True Wealth investments.

Kerry Rupp is a general partner of True Wealth Ventures. She previously led DreamIt, founded Holiday Golightly and held technology-company vice-president roles. She has taught NSF I-Corps entrepreneurship and earned an MBA at Harvard and bachelor’s degree at Duke.

Sara T. Brand founded True Wealth Ventures and works with women-led health and environmental businesses on strategy, operations and governance. She previously worked in venture capital, consulting and technology-company operating roles and co-founded512Brewing. She studied mechanical engineering at UT Austin and green design/manufacturing at Berkeley.

San Francisco director of finance at Polaris since2018, overseeing management-company accounting. Earlier finance experience includes more than ten years as Hummer Winblad Venture Partners’ controller.

San Francisco executive assistant and office manager at Polaris since2025. Previous administrative roles include FCB Global, VantagePoint Capital and Intuit.

Polaris executive assistant to Terry McGuire since2002. Since2010 also co-founder and executive administrator of the Global Venture Capital Congress, coordinating its annual meetings.

New York executive assistant and office manager at Polaris since2024. Holds a comparative-literature degree from Brigham Young University and previously provided executive support in business aviation.

Polaris executive assistant since2001, supporting Jon Flint and subsequently the healthcare team including Alan Crane. Previously supported executive leadership at Allaire Corporation.

Office coordinator at Polaris’ Boston office since2022. Previously an assistant office manager at Above the Rim sports complex.

Polaris portfolio analyst since2002, supporting finance and investor relations. Previously worked in audit, cost accounting and investment pension finance at John Hancock; studied finance at Siena College.

Boston senior operations associate at Polaris since2019. Previously worked at The Fulham Group, supporting office management and finance operations.

Polaris director of operations and limited-partner relations since2011, responsible for administration and special projects. Previously supported executives at Pixar and Sony’s Crackle.

Polaris founding partner with early-stage investing experience in medical and information technologies. Earlier venture positions include Burr, Egan, Deleage & Co.; co-founded Polaris in1996.

Polaris director of legal and investment analytics in San Francisco since2019. Previously a quantitative-analysis manager and senior corporate paralegal at Latham & Watkins. Studied mathematics at UCLA, obtained paralegal certification at San Francisco State and an MBA at Berkeley Haas. Distinct from Form Energy’s attorney and interim general counsel Brian Lewis.

Singapore partner at Polaris focused on healthcare technology, medical technology and care delivery. Earlier roles span Singapore’s SingHealth, National University Health System and Ministry of Health.

San Francisco accounting manager at Polaris since2018, working on management-company accounting. Previously spent more than fourteen years in accounting positions at VantagePoint Capital Partners.

New York principal at Polaris, focused on biotechnology and healthcare; joined in2022. Previously worked in Bain’s healthcare practice and helped establish Glympse Bio’s diagnostic technology.

Executive assistant supporting Polaris’ New York office since2023. Her earlier executive-support career spans finance, hospitality and other industries, including Goldman Sachs and SBE.

San Francisco chief financial officer at Polaris since2017. Oversees fund accounting, reporting and compliance and works with the finance, investment and legal teams.

Boston-based founding partner who established Polaris in1996 with Steve Arnold and Terry McGuire. Earlier venture experience includes Burr, Egan, Deleage & Co.; his career began in law.

Boston executive assistant and office manager at Polaris since2018. Previously provided administrative support to nonprofit organizations and worked in historic-site interpretation.

Polaris general counsel and chief compliance officer in San Francisco since2019. Supports legal, regulatory and operational work, fund formation, management and portfolio financing transactions.

Polaris entrepreneur partner since2002, building and financing healthcare companies. His company-building experience includes Zag Bio and multiple founder, chief-executive and chair positions.

Singapore entrepreneur partner at Polaris since2023, working on building and scaling healthcare businesses. Previously a life-sciences investment director at Temasek International.

Geney Park was published as a Bioluminescence Ventures Operating Partner who joined in2024. Previously she supported Ossium Health’s executive leadership and managed events and marketing for its bone-marrow banking business. Earlier work covered marketing and communications in health, wellness, fitness and technology training. She studied psychology at UC Riverside. This describes the archived2024–25 manager roster; continuing2026 BLV employment is not independently established.

Fund controller at Polaris since2022, responsible for fund administration and reporting. Previously an audit senior manager in BDO’s asset-management practice, with venture and private-equity experience.

Shailaja Uttamsingh joined Bioluminescence Ventures as Partner in2023 and led clinical and translational-science work. Her earlier oncology-development experience includes Exelixis, Celgene/BMS, Oncomed, Genentech and Amgen. She trained in biomedical sciences at Mount Sinai, biotechnology at Maharaja Sayajirao University of Baroda and physiology at Presidency College. Her university’s March2026 biography describes the BLV role as past and identifies subsequent clinical/venture advisory work; she is not presented as a current active BLV partner.

Andy Seid was published as a Bioluminescence Ventures Partner who joined in2023. Earlier he advised life-sciences companies in Bank of America’s global healthcare investment-banking group and held related positions at Leerink and UBS. His operating experience includes business development and strategic finance at Genentech and Sangamo. He studied molecular/cell biology and economics at Berkeley. The archived2024–25 BLV title does not establish a current2026 appointment or ownership of former-employer transactions.

Chloe Kim was published as a Bioluminescence Ventures Partner who joined in2022. Trained in biomedical engineering and cell biology, her expertise spans regenerative medicine, oncology, immunology and neuroscience. Earlier she worked in biopharmaceutical business development and strategy and consulted on life sciences at Charles River Associates. She earned Wisconsin–Madison biomedical-engineering graduate degrees and a Berkeley undergraduate degree. This describes the archived manager roster; her current public self-profile lists a stealth startup, so continuing BLV employment is not inferred.

Kouki Harasaki founded Bioluminescence Ventures and was published as its Founding/Managing Partner. Previously he led life-sciences investing at M12/Microsoft Ventures and was a senior partner with Andreessen Horowitz’s Bio Fund. His earlier work included drug discovery, pharmacology, finance and business development at Novartis and Baxalta/Shire. He studied molecular and cellular biology at Cornell, earned a Cambridge clinical-biochemistry doctorate and a Harvard MBA. The BLV role is documented by dated primary announcements and the archived2024–25 roster; continuing2026 manager activity is unverified.

Shapes Atlas AI’s development analytics services. Previously led infrastructure analytics at CPCS; background in systems planning and investment advisory across energy, transport, water and urban infrastructure.

Atlas AI co-founder with academic expertise in earth-system science, agricultural economics, food security and environmental research.

Works with Atlas AI’s Applied Data Science team to turn research into products. Background in statistics, sustainability and sensor-based data research.

Leads Atlas AI’s Innovation Team. Research and industry experience across computer vision, machine learning and global satellite-image analytics, including the European Commission Joint Research Centre and DigitalGlobe/Maxar.

Atlas AI co-founder who advises its team on machine learning technology. Academic background in computer science and AI research at Stanford.

Solutions engineer working with customers across Africa. Background in geospatial, remote sensing, drone and healthcare startups, including leading systems work at Flare.

Works on geospatial products with Atlas AI’s Innovation Team. Background in drone geotracking, remote sensing and autonomous systems research.

Develops machine learning workflows to track socioeconomic indicators. Previously worked on plant-image analysis and species identification at Greenstand.

Develops, tests and delivers geospatial analytical solutions for Atlas AI customers and partners.

Leads Atlas AI and serves on its board. Background in renewable energy, semiconductors and development data; previously at Incandescent, Premise Data and Astonfield Renewables.

Atlas AI board member whose published biography identifies him as an Airbus Ventures partner overseeing EMEA activities and strategic links to Airbus.

Published in Atlas AI’s current board directory with Textio as her external affiliation.

Atlas AI co-founder and board member. Stanford professor researching applications of data science to agriculture and food security.

Atlas AI board member and independent adviser. Previously held senior strategy, program and innovation roles at The Rockefeller Foundation.

Global Investor Relations professional as listed in Mammoth Scientific’s public directory. The firm describes international operating experience, business relationships across different regions and support for its global investors. The linked individual biography returns a missing-page response, so more specific prior employers, education and appointment dates are unverified.

Investor Relations professional at Mammoth Scientific. Her published responsibilities include coordinating projects and investor and adviser relationships, drawing on project management, business development and customer-facing experience. Her own biography lists prior business-to-business marketing and project-management work and a degree from Taylor University.

Vice President of Finance and Business Development as listed by Mammoth Scientific. The public directory describes responsibility for investor relations, portfolio due diligence and business development supporting the executive and investment teams. The linked individual page currently has no substantive biography, so further career and education details are unverified.

Co-founder and General Partner of Mammoth Scientific. He works on private-investment technology infrastructure, automated workflows and communications with investors and portfolio companies. His published career includes Orion, co-founding Mineral Interactive and a marketing role after its acquisition by Carson Group; Mammoth’s biography also identifies him as CEO of Milemarker.

Co-founder and General Partner of Mammoth Scientific, also published professionally as Kim Mackrill. She works on organizational integration, operations and data and technology processes for the investment platform and portfolio companies. She co-founded Mineral Interactive, which was acquired by Carson Group in 2018, and her Mammoth biography describes subsequent marketing and client-experience work and a role at Milemarker.

General Partner and Chief Legal Officer as separately published by Mammoth Scientific. Her legal work covers company transactions, governance and regulatory and commercial risks for founders and portfolio companies. She has served as in-house general counsel and outside counsel, and her own biography lists Northwestern College and Mitchell Hamline School of Law.

Neurosurgeon, co-founder and General Partner of Mammoth Scientific. He focuses on medical devices, healthcare software analytics and surgical technologies, helping companies develop clinical evidence, regulatory pathways and value-based reimbursement. His published background includes Duke undergraduate and medical education, Johns Hopkins residency and fellowship, and neurosurgical practice in Charlotte.

Co-founder and General Partner of Mammoth Scientific. His published work covers portfolio-founder support, investor relationships and financial, tax and operating strategy. He previously led a physician-focused wealth-management firm and has invested in private healthcare, fintech and other businesses. Mammoth’s fund committee and legal fund filings also identify him as CEO and operating manager; his own biography lists Indiana University and Harvard Business School executive education.

Joined NovaCapital as Management Assistant in 2022 and became Office Manager in 2023; previously Executive Assistant at Ariston Group and Modiano&Partners.

Business administration graduate with five years at PwC Milan; joined NovaCapital in 2022 after a role in the luxury sector.

Joined NovaCapital in 2023 after bachelor’s and master’s degrees in finance at Bocconi.

Corporate finance graduate from Luiss with experience at PwC, Kartesia and Alantra, and co-founder of a B2B SaaS startup.

Joined NovaCapital in 2021 following audit and M&A transaction services roles at EY and PwC; studied business at Bocconi and Grenoble.

Ariston Group finance and treasury executive; coordinates Merloni Holding Group’s financial matters since 2008.

Also Managing Director of Pragma Invest. Has investment banking and private equity experience at Salomon Smith Barney, Flemings and Synergo; joined Merloni Holding Group in 2013.

Executive Chairman of Ariston Group and Merloni Holding, with earlier McKinsey experience and a Bocconi business degree.

Shelley Graves joined S3 Ventures in 2009 and manages accounting, financial reporting, budgeting and compliance as Controller. She also supports HR and administrative operations. Her prior accounting work includes Union Pacific Resources and Cable Com.

Kathryn Deebel joined S3 Ventures in 2025 and leads marketing, community building, the firm’s professional network and internal operations. Her prior experience includes Quiet Capital, Gaingels and Golden Ratio. She studied finance at Penn State.

Will Omberg, also named William Omberg in the firm’s fund announcement, joined S3 Ventures in 2025 and is currently Senior Associate. He previously spent four years in technology investment banking at Jefferies working on M&A and equity financings. He studied commerce at the University of Virginia.

Kevin Haley joined S3 Ventures in 2025 as an Associate. He previously worked as an early product manager at Starburst Data on enterprise and SaaS products. He holds business and finance degrees from Boston College.

Anthony Marfisi joined S3 Ventures in 2024 as an Associate evaluating investments and supporting portfolio companies. He previously worked at DCA Asset Management on technology-company analysis and transaction advisory, and studied finance at Nebraska.

Nicole Bentz joined S3 Ventures in 2021 and is Vice President, evaluating investments and supporting companies including BrainCheck, QbDVision and Sunthetics. Her previous work includes Flyover Capital and PwC. She studied accounting at the University of Kansas and previously held a Missouri CPA license.

Joe Curry is a Principal at S3 Ventures, evaluating investments and supporting portfolio companies. His current firm biography and team directory identify this role; a native employer-published portrait accompanies the biography.

Aaron Perman is a General Partner at S3 Ventures investing in early-stage business technology and healthcare technology. His portfolio work includes Mythic, Hydrolix, Crogl and Sunthetics. He previously led Qualia Media through its acquisition, invested at Western Standard and worked in corporate strategy at Southern California Edison. He studied international business at USC.

Eric Engineer joined S3 Ventures in 2018 and is a General Partner. His portfolio board work includes Buzz Solutions, Kamiwaza, MontyCloud and QbDVision. He previously led Invodo through its acquisition, invested at Sevin Rosen Funds and worked at Microsoft and Trilogy. He holds an MBA from Harvard and computer-science degrees from Rice. Eric Engineer’s current S3 Ventures biography explicitly lists Kamiwaza among his portfolio boards; the January2025 Kamiwaza SEC filing independently names him as a director. This institutional affiliation is distinct from a personal investment.

Nadia Tarolli Schmidt is a Swiss lawyer and certified tax expert and a partner at VISCHER since 2010. Her current VZ corporate-governance biography explicitly lists her board membership at BiomedVC. She studied law at the University of Basel and advises on tax, social security and corporate matters. Her external board and law-firm affiliations provide identity context and are not treated as personal investment checks.

Ulrich Vischer is a Swiss attorney and senior counsel at VISCHER. He previously headed legal and tax work at an international insurer and served twelve years in the Basel City government overseeing finance. An official November 2018 Swiss commercial-register notice appointed him chair of BioMedPartners; the latest current primary firm team directory does not list statutory directors, so the legal-chair title is explicitly qualified by its last directly verified appointment notice.

Ulf Grawunder was appointed an entrepreneur in residence at BiomedVC in April 2026. He co-founded and leads T-CURX and previously built 4-Antibody and NBE-Therapeutics. He trained in biochemistry and immunology and earned his doctorate at the University of Basel. These are institutional manager affiliations; no personal portfolio investment is inferred.

Olivier Morand is a venture partner at BiomedVC and senior adviser to Scenic Biotech. His earlier work includes co-founding and leading Azafaros and pharmaceutical development roles at Actelion, Idorsia, Merck and Roche. He studied biology and genetics at Paris VII and executive management at IMD. These are institutional manager affiliations; no personal portfolio investment is inferred.

Mattias Ivarsson is an entrepreneur in residence at BiomedVC and founding CEO of Salvina Therapeutics. He previously founded Inositec during an ETH Zurich fellowship; that company was acquired by Vifor Pharma. He trained in biomedical engineering and pharmaceutical sciences and earned a doctorate at ETH Zurich. These are institutional manager affiliations; no personal portfolio investment is inferred.

David Urech is an antibody engineer and biotech entrepreneur appointed as a BiomedVC venture partner in April 2026. He co-founded Numab Therapeutics and Yellow Jersey Therapeutics and previously led research and development at ESBATech. He studied biochemistry at the University of Basel and molecular biology/neuroscience at the University of Zurich. These are institutional manager affiliations; no personal portfolio investment is inferred.

Claudia Ulbrich is a physician and biotechnology entrepreneur appointed as a BiomedVC venture partner in its April 2026 announcement. She co-founded and led Cardior Pharmaceuticals through its acquisition by Novo Nordisk. Her background also includes LipoNova and advisory work in biotechnology strategy and corporate development. These are institutional manager affiliations; no personal portfolio investment is inferred.

Marianna Feretzaki joined Biomed in 2026 as a senior associate. She previously led scientific work and acted as CEO at Rejuveron Telomere Therapeutics. She earned a genetics and genomics doctorate at Duke University after undergraduate biology study at the University of Crete. These are institutional manager affiliations; no personal portfolio investment is inferred.

Morgan Hunter joined Biomed in 2022 and is listed as investment manager with BiomedVC. His earlier entrepreneurial research included the planned ETH Zurich spin-off Emuna Therapeutics. His scientific training covers pharmaceutical immunology, vascular biology and protein engineering. These are institutional manager affiliations; no personal portfolio investment is inferred.

Stefan Fäs joined Biomed as group CFO in 2010 and is currently listed as CFO and partner for both manager teams. His previous work included Helbling Corporate Finance, Ernst & Young and UBS Asset Management. He holds graduate degrees in biology and economics and a certified-auditor qualification. These are institutional manager affiliations; no personal portfolio investment is inferred.

Valentin Piëch is currently listed as managing partner with both BioMedPartners and BiomedVC. He initially joined Biomed in 2015 and founded VP Venture Partners in 2020. His earlier experience includes Nextech Invest. He holds a neuroscience doctorate from Rockefeller University and graduate degrees in cognitive/neural systems and mechanical engineering. These are institutional manager affiliations; no personal portfolio investment is inferred.

Markus Hosang joined BioMedPartners in 2004 following venture investing at MPM Capital and approximately two decades of pharmaceutical research leadership at Roche. He studied biochemistry at ETH Zurich and undertook postgraduate training at Stanford and the University of Washington. These are institutional manager affiliations; no personal portfolio investment is inferred.

Aristotelis Nastos joined Biomed as managing partner in 2023. He previously headed life-sciences investing at NRW.BANK and worked at Peppermint and Creathor Ventures. His scientific background includes biology, a doctorate in cell biology and postdoctoral research at King’s College London. These are institutional manager affiliations; no personal portfolio investment is inferred.

Medical-device executive with more than20 years of industry experience. Worked at Medtronic’s EMEA headquarters and helped grow TriVascular and LimFlow through fundraising and acquisitions. Supports early-stage Greek medtech companies as an adviser and angel investor.

Finance and accounting professional with experience in deal screening and portfolio metrics; holds a master’s degree in accounting and finance from the Warsaw School of Economics.

Operations and business development professional with experience leading strategic initiatives and operational processes; studied economics and digital transformation at Koźmiński University.

Also known as DJ Nag. Intellectual property strategy specialist, President of Innovaito LLC and Professor of Practice at Rutgers University, named to IAM Strategy300 in2026.

UiPath Vice President who helped scale the Bucharest startup into an international robotic process automation company.

Technology product professional with experience at Google, Microsoft, AWS and Snowflake; an angel investor active in Ukraine’s startup ecosystem.

Hungarian technology investor with experience in strategic exits including Tresorit and Index Tools, and formerly Head of Yahoo! Labs.

Microelectronics PhD with postdoctoral research experience at INSA Toulouse. Previously Managing Partner at Polish deeptech investor PIBIR.

Experienced fund finance executive who served as CFO at Nomad VC and Valuetech. Brings financial due diligence and transaction experience, with exits including Booksy.

Corporate finance and investment professional with more than20 years in M&A and investing. Previously an investment director at Newberg and Valuetech, with IPO and exit experience including ML System, Sat Revolution and T-Bull.

Technology entrepreneur and investor; formerly founded and chaired MIT Enterprise Forum Poland and served as Managing Partner at Valuetech, supporting Polish deeptech acceleration and seed investment.

Ken Chin is a partner at MQB Partners, a medical doctor and healthcare business owner with more than20years of experience. He previously co-owned a general medical practice acquired in2022 and is a Fellow of the Royal New Zealand College of General Practitioners. Since2016 he has provided clinical assessments of early-stage healthcare investments and strategic advice to healthcare businesses. His earlier research covered endocrinology and urology. He holds medical and human biology degrees from the University of Auckland and a postgraduate travel-medicine certificate from the University of Otago.

Scott McPhee is a partner at MQB Partners and an entrepreneurial scientist developing novel medicines since the late1990s. He participated in early gene-therapy programmes for neurodegenerative conditions and initial central nervous system AAV trials. He was a founding executive at Asklepios BioPharmaceutical, acquired by Bayer in2020; co-founded Chatham Therapeutics, acquired by Baxter; and joined the founding team of Bamboo Therapeutics, acquired by Pfizer. He also co-founded Torque Bio. He holds a molecular medicine doctorate from the University of Auckland and a public health master’s degree from Harvard University. Historical company transactions are not MQB investments or fundraising without separate proof.

Marko Bogoievski is a partner at MQB Partners. He previously led Infratil and infrastructure investment manager H.R.L. Morrison & Co as CEO, during a period in which their funds under management grew from $2.1billion to $25billion; those historical assets are not MQB fund closes. His career includes finance, sales and investment management across New Zealand, Australia and the United States. He holds a commerce and administration degree from Victoria University, an MBA from Harvard Business School, and is a Fellow Chartered Accountant.

Dave Maldonado was announced by Ramen VR’s CEO in February 2023 as the incoming design leader alongside art leader Giancarlo Surla. The issuer describes previous World of Warcraft and New World design leadership. A continuing 2026 staff role, exact employment start day and current photograph are not independently disclosed in the accessible primary sources.

Chandani Battle is the named author of Ramen VR’s December 2024 hackathon article. This primary publication establishes a credited contributor affiliation but does not disclose a precise employment title, start date or continuing staff status. No executive, marketing or operations position is invented.

Chris Gong co-founded the Unreal Engine AI assistant Flopperam with Ryan Thomas. Ramen VR’s June 2026 issuer announcement and Gong’s own acquisition post identify his joining Aura as Senior AI Engineer. His own GitHub account chris-gong links the Flopperam Unreal-engine MCP project now owned by Aura. This is a distinct person from the existing Arize AI engineer Chris Gong whose public profile is chrisgong52; their identities and affiliations are preserved separately.

Robert Espinoza’s own professional profile identifies Ramen VR and his 2026 Aura game-development work. His own earlier Paper Crane Games biography identifies an environment artist and co-founder, and provides the named genuine photograph. An unpublished current seniority level is not inferred. He is not automatically conflated with the historical Zenith credit Rob B.

Kristani Alcantara is identified as Director of Operations in Ramen VR’s December 2024 hackathon article and retains the Ramen affiliation on her own public professional profile. The historical Zenith press kit credits her as Operations Director. Meals for Unity’s own origin story also names her as a co-founder, a distinct outward nonprofit activity rather than Ramen financing.

Hisham Bedri is named in Ramen VR’s current public company directory and authored its March 2025 Speedrunning Game Development article. His primary MIT Media Lab profile identifies him as a former research assistant interested in spatial technologies, 3D displays and imaging. That historical academic affiliation and authentic MIT photograph are personal credentials, not an assertion that Aura is a brain-interface or clinical neuroscience product.

Kevin Calderone is named in Ramen VR’s current public company directory and lists the company on his own professional profile. His own earlier game-studio biography documents programming and design work. An exact current engineering grade and appointment day are not disclosed in the accessible primary directory and are not inferred from third-party organizational charts.

Giancarlo Surla is named in Ramen VR’s current public affiliation directory. The issuer’s February 2023 CEO letter announced his appointment to lead art direction alongside design lead Dave Maldonado. Surla’s own published professional recommendation identifies his role as Head of Art. He previously co-founded Paper Crane Games, whose own named profile supplies his genuine photograph.

Lauren Frazier-Silva, previously publicly known as Lauren Frazier, co-founded Ramen VR with Andy Tsen in 2019 and served as CTO. Her own current Silvermoon website identifies her as its founder after prior work at Google, Unity and Ramen VR; her older personal site still describes the Ramen CTO role. This Ramen affiliation is therefore historical rather than an assumed current executive appointment. Her own statement that she raised over USD46M at Ramen is a cumulative lower bound, not an additional cash round.

Andy Tsen co-founded Ramen VR in 2019 with Lauren Frazier. Its current primary company and Y Combinator profiles identify him as CEO, and the September 2026 Aura issuer release quotes him as CEO. Ramen VR develops AI agents for game creation and originally developed Zenith: The Last City. Company speed and market-coverage claims are not independently verified benchmarks.

Ammara Chaudhry is published by Blackbird Health as a certified registered nurse practitioner providing psychiatric care for children and families. Her biography describes nursing and specialized mental-health experience and study at UC Berkeley, George Mason, Drexel and Wilkes. The public clinical-network affiliation is distinguished from direct employment by the administrative management company.

Nicole Garber formerly served as chief medical officer for Blackbird Health’s clinical network. The company’s March 2, 2026 announcement explicitly introduces her successor Michael Tang and describes her departure to focus on eating-disorder work and advocacy. Older resources still publish her author and medical-reviewer bylines; these are historical content rather than evidence that she remains chief medical officer.

Matt Keener is a board-certified psychiatrist and co-founder of Blackbird Health. The company’s 2024 financing release describes his role in the 2021 relaunch alongside founder Amy Edgar. His self-published professional profile identifies child and adolescent and adult psychiatry training, neuroimaging research and a continuing co-founder affiliation. A current executive job at Blackbird is not inferred from his founder status.

Lucia Cortes is identified as a child and adolescent psychotherapist in Blackbird Health’s published patient story Confidence Comes Back. The source describes therapy and family support through its multidisciplinary model. The original story dates to 2024 and remains published; continued active clinical service and a current appointment date have not been independently established.

Bethany Barney, MSS, LCSW, is published by Blackbird Health as a diagnostician and director of clinical evaluation. Her clinical-author biography describes specialization in neurodevelopmental disorders and child and adolescent mental health, with comprehensive assessments for children and families. The affiliation is source-qualified to the published clinical biography and current resource byline; direct employment by the management company is not inferred.

Coleen Vanderbeek is published by Blackbird Health as a clinician and writer on autism and early childhood, with its clinical-author biography identifying her as director of autism and early childhood. Her stated focus is neurodevelopmental behavioral health and comprehensive care for children. The role reproduces the public biography; an exact appointment date or independently verified employment arrangement is unavailable.

Caronne Taylor Bloom is published by Blackbird Health as an education advocate and licensed professional counselor. Her biography describes experience as a therapist and educator and interests including executive function, ADHD, tic disorders, autism, OCD, depression and school advocacy. The affiliation is published clinical-network work and educational authorship, without a management-company employment claim.

Kevin Olivo, LCSW, is published by Blackbird Health as vice president of behavioral services. His responsibilities include clinical protocols, quality standards and organization-wide training to improve care delivery. His clinical leadership affiliation is distinguished from employment or supervision of licensed providers by the technology and management company.

Anita Cattrell is president and chief operating officer of Blackbird Health, as identified in its March 2026 leadership announcement. Her historical Living Goods biography describes earlier healthcare innovation leadership at Evolent Health and monitoring and evaluation work with Partners In Health in Rwanda. It also documents clinical-epidemiology doctoral training and biomedical-engineering education at Harvard and Northwestern. Her authentic portrait is from a 2020 institutional report and is identified as historical.

Nicholas Mediate is published in Blackbird Health’s clinical directory as a psychotherapist, with family therapy and video-game addiction among his specialties. The company’s October 2026 resource byline also identifies him as manager of behavioral health. The role is an affiliation with the independent clinical-practice network, rather than an assumed employment relationship with the management company.

Molly Kotocavage is published in Blackbird Health’s current directory as an occupational therapist, with sensory processing and picky eating among the stated specialties. Her affiliation is with the branded independent clinical practice network. This directory entry is not treated as proof that every clinic currently delivers occupational therapy treatment.

Patrice Griffin is published in Blackbird Health’s clinical directory with an LPC credential and specialties including cognitive behavioral therapy, dialectical behavior therapy and trauma therapy. The current company page spells her surname Griffen, while its named original photograph and clinical-author biographies use Griffin; these sources identify the same pictured clinician. Her relationship is a branded clinical-network affiliation rather than assumed management-company employment.

Gabrielle Derosier is published in Blackbird Health’s current clinical directory as a psychotherapist. Her listed areas include PTSD, anxiety, depression and sexual trauma, with an emphasis on supporting patients and their families. The clinical-network affiliation is distinguished from management-company employment.

Nikki Stone is published in Blackbird Health’s current clinical directory with the PMHNP-BC credential. Its listed specialties include anxiety, depression, mood disorders and PTSD. She is presented as part of the independent clinical practice network, without an assumed employment relationship with the management company.

Micah Munro is published in Blackbird Health’s current clinical directory as a psychotherapist. The directory names depression, anxiety, ADHD and OCD among her specialties. The affiliation is with the branded clinical network of independent medical practices; employment by Blackbird Health’s management company is not inferred.

Michael Tang joined Blackbird Health as chief medical officer on March 2, 2026. The organization describes him as board-certified in child and adolescent psychiatry, adult psychiatry, pediatrics and addiction medicine, with degrees from Harvard College, Harvard Medical School and Brandeis University. His published work concerns coordinated pediatric mental health care. Clinical oversight belongs to the independent provider-owned medical practices, rather than an assumed employment or supervisory relationship with the management company.

Amy Edgar founded the original clinic behind Blackbird Health in 2014. Its current directory identifies her as a founder and publishes her nursing education at DeSales University and the University of Pennsylvania, including family-practice and family-nurse-practitioner qualifications. The company’s 2024 financing release identified her as chief clinical officer. Clinical services are delivered through independent provider-owned practices supported by Blackbird’s technology and administrative platform.

Previously Senior Director of Business Development at Tempus AI; PhD in Biology and 15 years of oncology research and development at Pfizer. Leads commercial development for O-Predict and O-Target.

Lord David Prior advises Automata on healthcare systems and institutional strategy. Previously chaired the Care Quality Commission and NHS England and served as a UK health minister. His existing Axiom affiliation is preserved; the current Automata advisory affiliation does not establish a personal investment.

Dan Nomura is named Investment Advisory Board in Droia’s current public directory. The published professional background includes Professor of Chemical Biology and Molecular Therapeutics at the University of California, Berkeley; Director of the Novartis-Berkeley Translational Chemical Biology Institute; Co-Founder of Frontier Medicines; Founder of Vicinitas Therapeutics. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Ozi Amanat founded K2 Global in 2015 to invest in private technology companies. Its current issuer announcement identifies him as a solo venture capitalist.

LaevaCare publicly announced Viktoria as its first employee in April2026. Its earlier January update identified her communications internship and work writing pelvic-floor educational articles; a precise current employee job title is not published.

Engineer working on LaevaCare’s prototypes, support mechanics, manufacturing quality and technical product development.

Midwife developing and testing pelvic-floor support products with postpartum women. Also published under the shortened name Eva Dimon.

Registered nurse with marketing, commercialization and business-development experience; leads LaevaCare from clinical prototypes toward product sales.

Urogynecologist and obstetrician with more than40years of clinical experience in childbirth and pelvic-floor injuries. Leads LaevaCare’s medical foundations and product development.

Kiutra lists Carlo Germano Ravina in its Board and advisors directory as its NovaCapital representative. The directory does not specify a separate director or adviser title.

Lauren Martin is administrative assistant at Frist Cressey Ventures. Named on the firm’s current public team directory as administrative assistant. A detailed biography was not available from the accessible primary directory text.

Traci Few is manager, personnel and operations at Frist Cressey Ventures. Executive support and operations professional at FCV since 2021. Previously supported healthcare, property and legal executives, including at HCA and Parallon.

Owen McGrath is director of finance and operations at Frist Cressey Ventures. Named on the firm’s current public team directory as director of finance and operations. A detailed biography was not available from the accessible primary directory text.

Zach Johnson is chief financial officer at Frist Cressey Ventures. Finance professional at FCV since 2021. Previously an RSM tax manager advising investment funds; is a Tennessee CPA and studied accounting and finance at Marquette.

Zeena Johar is entrepreneur in residence at Frist Cressey Ventures. Healthcare entrepreneur who helped found Imagine Pediatrics and SughaVazhvu Healthcare. Previously led operations at Advantia Health and holds an ETH molecular diagnostics doctorate.

Jamie Kuntz is associate, partnership development at Frist Cressey Ventures. Joined FCV in 2023, supporting communications, digital media and portfolio marketing. Previously coordinated programmes at Vanderbilt’s nanoscale science institute and taught English literature.

Chloe Coulter is director of value creation at Frist Cressey Ventures. Joined FCV in 2023. Previously worked in human capital consulting at Deloitte and strategy, startup accelerators and innovation consulting at Innovator’s DNA.

Caroline Young is head of partnership development at Frist Cressey Ventures. Partnership leader at FCV since 2021. Previously helped launch NashvilleHealth and led the Nashville Health Care Council; has served on Cumberland Pharmaceuticals’ board.

Whit Emerson is investment associate at Frist Cressey Ventures. Healthcare operator and investor previously on Monogram Health’s strategy team and the founding team of virtual cardiac wellness company Motiv. Earlier worked at Bright Health and EY-Parthenon.

Tommaso Auerbach is senior associate at Frist Cressey Ventures. Investor at FCV since 2023, interested in AI and human health. Previously at Oxeon working on company creation, investing and executive search; studied at NYU.

Lydia Witty is investment associate at Frist Cressey Ventures. Investor at FCV since 2023. Previously a healthcare consultant at AArete and studied medicine, health and society at Vanderbilt.

William Trapnell is senior associate at Frist Cressey Ventures. Healthcare investor at FCV since 2021. Previously worked in Citi’s healthcare investment banking group and studied accounting at Tennessee.

Derek Dedeker is principal at Frist Cressey Ventures. Investor at FCV since 2022. Previously spent four years at Santé Ventures after working in financial institutions investment banking at Citi.

Matt Schappell is principal at Frist Cressey Ventures. Healthcare investor at FCV since 2019. Previously in Ziegler’s healthcare technology investment banking group and business development at a Universal Health Services hospital.

Harrison Frist is operating partner at Frist Cressey Ventures. Former CEO and founding team member of naviHealth, with earlier investing experience at Carlyle and banking experience at Goldman Sachs. Joined FCV as operating partner in April 2026.

J. Mark Tipps is partner & coo at Frist Cressey Ventures. Lawyer and organisational leader who joined FCV in 2023. Previously worked at Bass Berry & Sims and Walker Tipps & Malone and was Bill Frist’s Senate chief of staff.

Olivia Capra is partner at Frist Cressey Ventures. Healthcare investor previously at Kaiser Permanente Ventures and Convey Capital. Earlier supported Macro Trials and Cornerstone AI and covered specialty pharmaceuticals at Barclays.

Bryan Cressey is co-founder & senior advisor at Frist Cressey Ventures. Healthcare private equity investor and company builder who co-founded FCV. Studied economics at Washington and law and business at Harvard.

Duong Huynh is a published BrainCheck-affiliated cognitive-health research author. Peer-reviewed2025 studies document the company affiliation; a2026 job title or continued employment has not been inferred.

Kevin Sun is a published BrainCheck-affiliated cognitive-health research author. Peer-reviewed2025 studies document the company affiliation; a2026 job title or continued employment has not been inferred.

Yael Katz co-founded BrainCheck and formerly led it as CEO. The company’s own2019 review and2021 issuer financing release establish her founder role. Current operational employment is not assumed from historical biographies.

Liz Kwo is a physician appointed to BrainCheck’s board on January28,2026.

Supports science-based company sourcing, commercialisation, team development, and investment readiness. Previously led UniTartu Ventures and co-founded SEB Group’s Innovation Lab; serves on the EstVCA board.

Supports science-based business and growth projects while pursuing bioinformation technology and business administration studies at Aalto University.

International finance and technology executive with experience in fundraising, public listings, exits, IoT, healthcare connectivity, AI, semiconductors, and business development.

Former investment banker and technology entrepreneur with experience structuring international transactions and founding and advising startups.

Technology transfer and software entrepreneur experienced in creating and supporting university spinouts at Helsinki and Oxford. Leads Nordic Science Investments as CEO.

Genetics PhD and former Stanford visiting researcher with experience in academic commercialisation, biotechnology R&D leadership, oncology, and digital health.

Analyses technology innovation, competitive differentiation, and industry applicability.

Specialises in climate and sustainability technology, portfolio and fundraising support, and leading deals and portfolio work.

Supports marketing, communications, brand strategy, go-to-market planning, team design, ecosystem development, and portfolio companies.

Focuses on engineering innovation, intellectual property strategy, complex technology sales, product and commercial strategy, team building, and early growth.

Supports business development and scaling portfolio companies beyond the seed stage.

Focuses on biotechnology, medical technology, AI and machine learning, early research and development, and strategy.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s operating-partner network.

Published in Luminar’s operating-partner network.

Published in Luminar’s operating-partner network.

Published in Luminar’s operating-partner network.

Published in Luminar’s operating-partner network.

Published in Luminar’s operating-partner network.

Butterfly’s own current fund disclosure lists Henri Ailinpieti as Associate; its main team display omits him. The profile records the published disclosure role, with current employment requiring confirmation if the pages are inconsistent.

Rudolph Tanzi is a Harvard and Massachusetts General Hospital neuroscientist studying the genetics and biology of Alzheimer’s disease. Cerevance announced his scientific advisory appointment in October 2017; current tenure is unconfirmed.

Jeremy Nathans is a Johns Hopkins professor and HHMI investigator studying molecular mechanisms of neural development and visual function. Cerevance appointed him a scientific adviser in October 2017; his current advisory tenure has not been reconfirmed.

Caroline Quay is a Cerevance board director and managing partner of MQB Partners, a New Zealand biotechnology investor. Her healthcare investment experience includes medical devices, digital health, drug and biologic development, and diagnostics. She was Global General Counsel at Fisher & Paykel Healthcare and a founding executive of Aroa Biosurgery, which listed on the ASX in2020. She began her career in mergers and acquisitions, private equity and venture-investment law. She holds honours law and commerce degrees from the University of Auckland, received the EY/NZ Asian Leaders Scholarship for the University of Virginia Darden programme in2015, and was awarded the SBCWarburg finance scholarship. Earlier affiliations and public-company transactions are career history, distinct from current institutional checks.

Campbell Murray is a Cerevance board director and co-founder and managing partner of Double Point Ventures. His prior investment roles include Bioluminescence Ventures, Agent Capital and Novartis Venture Fund. Campbell Murray joined Bioluminescence Ventures as Senior Partner in2024. Earlier he invested at Agent Capital and spent more than sixteen years at Novartis Venture Fund, and his operating experience includes Diabetes Free and Intima Bioscience. He trained in medicine at Auckland and earned Harvard business and public-policy degrees. His BLV appointment is historical: current Cerevance/DoublePoint sources identify his subsequent co-founder/managing-partner work at Double Point Ventures; those roles and authentic current portrait are preserved.

Brad Margus chairs Cerevance’s board and was its founding chief executive until 2022. He also founded and led Envoy Therapeutics and Perlegen Sciences, and established the A-T Children’s Project.

David Lubner is an independent director of Cerevance. His life sciences finance experience includes CFO positions at Ra Pharmaceuticals, Tetraphase, PharMetrics and ProScript.

Aoife Brennan is a Cerevance board director and Climb Bio’s president and chief executive officer. Her earlier career includes leadership at Synlogic and Biogen; she trained in medicine at Trinity College Dublin.

Thomas Yonker leads operations at Cerevance. His biopharmaceutical project management career includes Neurana, Upjohn, Synergen, Abgenix and PaxVax.

Nigel Ramsden leads drug discovery at Cerevance. His earlier industry experience includes GSK, Cellzome and RxCelerate, across multiple therapeutic modalities and stages of development.

Nicola Brice leads neuroscience at Cerevance. Her drug development work spans neurodegeneration, psychiatry and pain, from target selection through clinical studies. She trained at UCL and Oxford.

Johnna Simões leads corporate development at Cerevance. She previously worked in corporate development at Neurana and held biopharmaceutical strategy, business development and investor relations roles at Anthera and Trius.

Rob Middlebrook is Cerevance’s chief financial officer. His earlier roles include CFO of Envoy Therapeutics, corporate development leadership at Perlegen Sciences and senior investment management positions at Fidelity. Cerevance’s releases also identify him as Robert Middlebrook.

Mark Carlton is Cerevance’s chief scientific officer, with experience spanning academic research and drug development. He co-founded Paradigm Therapeutics and previously led Takeda’s Cambridge UK research site as president and chief scientific officer.

Craig Thompson leads Cerevance as chief executive and serves on its board. His biotechnology and pharmaceutical career includes Neurana, Merck, Pfizer and Trius. This executive is distinct from cancer researcher Craig B. Thompson.

Charlie Plauche appears in BrainCheck’s current Board of Directors & Advisors directory. Exact appointment date and the directory’s director-versus-adviser classification are not specified. Charlie Plauche joined S3 Ventures in 2010. The firm’s current team directory calls him Managing Director, while his individual biography calls him General Partner; both current public labels are retained. His portfolio board work includes BrainCheck, Cloverleaf AI, Interplay Learning and LeanDNA. Before S3 he worked at Harbert Private Equity Funds; he holds degrees from Mississippi and the University of Texas.

Xaviera Xiao is a published BrainCheck-affiliated cognitive-health research author. Peer-reviewed2025 studies document the company affiliation; a2026 job title or continued employment has not been inferred.

Bin Huang is BrainCheck Principal Scientist and the named principal investigator for its2025 NIH eConsult award. He earned a computational-biology PhD at Rice in2017 and works on cognitive assessments, cognitive-care planning and AI research.

Matthew (Matt) Cerullo’s published BrainCheck leadership-page biography identifies an April2022 Chief Revenue Officer appointment. His biography remains published but the current visible roster lacks a separate card; continued employment is not independently confirmed.

Stephen Bekanich is BrainCheck CMO, appointed March10,2026. A physician and Iris Healthcare co-founder, he previously held Aledade and Ascension roles. He studied medicine at Buffalo and trained at Utah.

Danny McPherson leads BrainCheck engineering, with previous Iris Healthcare and Aledade software-platform leadership. He studied computer science at the University of Texas.

Danielle Yoon leads BrainCheck marketing, with prior digital-pharmacy and enterprise-software experience. She studied communications and psychology at Boston University. Her directory heading says VP Marketing and biography describes Head of Marketing.

Andrew Chen leads a BrainCheck product program and previously co-founded Iris Healthcare, serving as Chief Product Officer and later Aledade VP Product. This Austin healthcare operator is distinct from the Andreessen Horowitz investor of the same name.

Steve Wardle is BrainCheck President, appointed in July2025. He co-founded and led Iris Healthcare before its acquisition by Aledade, then served in Aledade practice-health leadership. He completed an MBA at Duke.

Elaine Cannizzaro leads BrainCheck operations after clinical-operations leadership at Iris Healthcare and a decade at Vital Decisions. She studied communication at William Paterson University and psychology and counseling at Goddard College.

Robert Terrell leads product development at BrainCheck, drawing on healthcare, pharmacy and patient-engagement technology experience. He studied management information systems at the University of Louisiana at Lafayette.

Bassel Samman leads BrainCheck technology and information security, joining in2015. His work covers software, infrastructure and cybersecurity. He previously worked at Rackspace and studied computer science at UMass Amherst.

Judd Rabb is BrainCheck CFO and a certified accountant with technology-company finance experience, including OJO Labs, Digital Pharmacist, Main Street Hub, SolarBridge, Bazaarvoice and Silicon Laboratories. He studied accounting at Texas A&M.

Molly Penna leads customer success at BrainCheck, joining in2021. She has worked on healthcare-system implementations and Epic integration, following healthcare strategy work at Deloitte. She studied industrial engineering at the University of Miami.

Mary Patterson leads BrainCheck clinical and regulatory work, with neuroscience, Alzheimer’s and neurovascular trial experience. She studied neuroscience at Ohio University and aging and neuroscience at the University of South Florida.

Chris Loughlin leads BrainCheck as CEO, joining in October2024 after running Pixiu Investments and Digital Pharmacist and serving as Travelzoo CEO. He studied technology management and completed MBAs at Berkeley and Columbia.

Scott Miller is venture partner at Next Coast Ventures, according to its current official roster. The firm’s published career biography records: EIR @ NCV | Co-Founder & VP Product @ TrustRadius | COO @ Vast (acq. Vroom) | Strategic Planning / APAC Ops @ SolarWinds | Austin Ventures | pcOrder / Trilogy Software | MIT BS + M.Eng, CSEE | HBS MBA. Outside executive and board references are reported as career history, with current status at each separate organisation not independently assumed.

Jason Dorsey is venture partner at Next Coast Ventures, according to its current official roster. The firm’s published career biography records: Gen Z and Millennial Expert | Global Keynote Speaker | 5x Author, 3x Founder | Led 70+ Research Studies | Corp Board Member | New book: Zconomy. Outside executive and board references are reported as career history, with current status at each separate organisation not independently assumed.